Imanishi M, Negita M, Ikegami M, Nishioka T, Ishii T, Uemura T, Kunikata S, Kanda H, Matsuura T, Akiyama T
Department of Urology, Kinki University School of Medicine.
Nihon Hinyokika Gakkai Zasshi. 1991 Jun;82(6):907-13. doi: 10.5980/jpnjurol1989.82.907.
Our induction immunosuppressive therapies were carried out on patients split into three groups. The first group of 25 recipients were treated with regimen I [cyclosporin (CsA); 12 mg/kg/day and prednisolone (Pred)]. The second group of 16 recipients were treated with regimen II [CsA; 6 mg/kg/day, Pred and mizoribine (MIZ) or azathioprine (AZA)]. The third group of 14 recipients were treated with regimen III [CsA; 10 mg/kg/day, Pred and MIZ or AZA]. There was no significant difference among the three groups in renal function three months after renal transplantation. The frequency and grade of rejection were significantly higher in Group II than in the other groups. One of group I had CsA nephrotoxicity and none of group III had liver dysfunction three months after renal transplantation. Group I had a higher incidence of posttransplant hypertension. Hypertension of group I was very severe. We concluded that the triple-drug therapy on group III was the best induction immunosuppressive therapy after renal transplantation of the above three.
我们对患者进行诱导免疫抑制治疗，将其分为三组。第一组25名受者采用方案I进行治疗[环孢素（CsA）；12毫克/千克/天和泼尼松龙（Pred）]。第二组16名受者采用方案II进行治疗[CsA；6毫克/千克/天、Pred和咪唑立宾（MIZ）或硫唑嘌呤（AZA）]。第三组14名受者采用方案III进行治疗[CsA；10毫克/千克/天、Pred和MIZ或AZA]。肾移植三个月后，三组之间的肾功能无显著差异。第二组的排斥反应频率和分级明显高于其他组。肾移植三个月后，第一组中有1人出现CsA肾毒性，第三组中无人出现肝功能障碍。第一组移植后高血压的发生率较高。第一组的高血压非常严重。我们得出结论，上述三种方案中，第三组的三联药物疗法是肾移植后最佳的诱导免疫抑制疗法。
